EKF Diagnostics Holdings Plc (EKF) - Total Assets

Latest as of December 2025: GBX81.14 Million GBX ≈ $9.87K USD

Based on the latest financial reports, EKF Diagnostics Holdings Plc (EKF) holds total assets worth GBX81.14 Million GBX (≈ $9.87K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check EKF cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

EKF Diagnostics Holdings Plc - Total Assets Trend (2001–2025)

This chart illustrates how EKF Diagnostics Holdings Plc's total assets have evolved over time, based on quarterly financial data. Explore EKF long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

EKF Diagnostics Holdings Plc - Asset Composition Analysis

Current Asset Composition (December 2025)

EKF Diagnostics Holdings Plc's total assets of GBX81.14 Million consist of 38.1% current assets and 62.0% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 19.5%
Accounts Receivable GBX6.74 Million 8.3%
Inventory GBX8.30 Million 10.2%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX3.75 Million 4.6%
Goodwill GBX24.14 Million 29.8%

Asset Composition Trend (2001–2025)

This chart illustrates how EKF Diagnostics Holdings Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EKF Diagnostics Holdings Plc market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: EKF Diagnostics Holdings Plc's current assets represent 38.1% of total assets in 2025, an increase from 3.8% in 2001.
  • Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, up from 0.3% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, a decrease from 95.0% in 2001.
  • Asset Diversification: The largest asset category is goodwill at 29.8% of total assets.

EKF Diagnostics Holdings Plc Competitors by Total Assets

Key competitors of EKF Diagnostics Holdings Plc based on total assets are shown below.

Company Country Total Assets
Shenzhen New Industries Biomedical
SHE:300832
China CN¥9.58 Billion
Inspire Medical Systems Inc
NYSE:INSP
USA $911.38 Million
SS Innovations International Inc. Common Stock
NASDAQ:SSII
USA $90.55 Million
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
China CN¥1.59 Billion
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
China CN¥805.10 Million
Stratec SE
XETRA:SBS
Germany €443.38 Million
Scandinavian Medical Solutions AS
CO:SMSMED
Denmark Dkr205.86 Million
Duearity AB
ST:DEAR
Sweden Skr10.84 Million

EKF Diagnostics Holdings Plc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.16 4.44 2.26
Quick Ratio 3.04 3.29 1.83
Cash Ratio 0.00 0.00 0.00
Working Capital GBX23.45 Million GBX22.11 Million GBX24.54 Million

EKF Diagnostics Holdings Plc - Advanced Valuation Insights

This section examines the relationship between EKF Diagnostics Holdings Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.55
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) -0.7%
Total Assets GBX81.14 Million
Market Capitalization $1.36 Million USD

Valuation Analysis

Below Book Valuation: The market values EKF Diagnostics Holdings Plc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: EKF Diagnostics Holdings Plc's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for EKF Diagnostics Holdings Plc (2001–2025)

The table below shows the annual total assets of EKF Diagnostics Holdings Plc from 2001 to 2025.

Year Total Assets Change
2025-12-31 GBX81.14 Million
≈ $9.87K
-0.74%
2024-12-31 GBX81.75 Million
≈ $9.95K
+1.11%
2023-12-31 GBX80.85 Million
≈ $9.84K
-9.45%
2022-12-31 GBX89.29 Million
≈ $10.86K
-22.44%
2021-12-31 GBX115.12 Million
≈ $14.01K
+13.68%
2020-12-31 GBX101.27 Million
≈ $12.32K
+16.23%
2019-12-31 GBX87.13 Million
≈ $10.60K
+7.06%
2018-12-31 GBX81.38 Million
≈ $9.90K
+5.47%
2017-12-31 GBX77.16 Million
≈ $9.39K
-6.40%
2016-12-31 GBX82.43 Million
≈ $10.03K
+14.67%
2015-12-31 GBX71.89 Million
≈ $8.75K
-47.05%
2014-12-31 GBX135.78 Million
≈ $16.52K
+123.60%
2013-12-31 GBX60.72 Million
≈ $7.39K
+8.98%
2012-12-31 GBX55.72 Million
≈ $6.78K
-5.14%
2011-12-31 GBX58.73 Million
≈ $7.15K
+63.24%
2010-12-31 GBX35.98 Million
≈ $4.38K
+462.44%
2009-12-31 GBX6.40 Million
≈ $778.33
+11.48%
2008-12-31 GBX5.74 Million
≈ $698.15
+3.11%
2007-12-31 GBX5.57 Million
≈ $677.10
+7.83%
2006-12-31 GBX5.16 Million
≈ $627.94
+6.57%
2005-12-31 GBX4.84 Million
≈ $589.25
-27.25%
2004-12-31 GBX6.66 Million
≈ $809.96
+5.23%
2003-12-31 GBX6.33 Million
≈ $769.69
+1033.69%
2003-06-30 GBX558.00K
≈ $67.89
-91.32%
2002-12-31 GBX6.43 Million
≈ $782.59
+18.06%
2001-12-31 GBX5.45 Million
≈ $662.86
--

About EKF Diagnostics Holdings Plc

LSE:EKF UK Medical Devices
Market Cap
$1.36 Million
GBX11.15 Billion GBX
Market Cap Rank
#30299 Global
#754 in UK
Share Price
GBX25.90
Change (1 day)
-3.36%
52-Week Range
GBX21.80 - GBX31.90
All Time High
GBX78.21
About

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit rea… Read more